154 related articles for article (PubMed ID: 33817161)
1. Predictive Significance of Serum MMP-9 in Papillary Thyroid Carcinoma.
Xu D; Su C; Guo L; Yan H; Wang S; Yuan C; Chen G; Pang L; Zhang N
Open Life Sci; 2019 Jan; 14():275-287. PubMed ID: 33817161
[TBL] [Abstract][Full Text] [Related]
2. Serum MMP-2 as a potential predictive marker for papillary thyroid carcinoma.
Shi Y; Su C; Hu H; Yan H; Li W; Chen G; Xu D; Du X; Zhang P
PLoS One; 2018; 13(6):e0198896. PubMed ID: 29949618
[TBL] [Abstract][Full Text] [Related]
3. Immunohistochemical analysis of matrix metalloproteinase-9 predicts papillary thyroid carcinoma prognosis.
Liu X; Su C; Xu J; Zhou D; Yan H; Li W; Chen G; Zhang N; Xu D; Hu H
Oncol Lett; 2019 Feb; 17(2):2308-2316. PubMed ID: 30675296
[TBL] [Abstract][Full Text] [Related]
4. Predictive significance of serum dipeptidyl peptidase-IV in papillary thyroid carcinoma.
Zhang N; Cong X; Zhou D; Guo L; Yuan C; Xu D; Su C
Cancer Biomark; 2019; 24(1):7-17. PubMed ID: 30594915
[TBL] [Abstract][Full Text] [Related]
5. Preoperative platelet distribution width-to-platelet ratio combined with serum thyroglobulin may be objective and popularizable indicators in predicting papillary thyroid carcinoma.
Jin J; Wu G; Ruan C; Ling H; Zheng X; Ying C; Zhang Y
J Clin Lab Anal; 2022 Jun; 36(6):e24443. PubMed ID: 35441746
[TBL] [Abstract][Full Text] [Related]
6. Serum Matrix metalloproteinase-9 (MMP-9) can help identify patients with papillary thyroid cancer at high risk of persistent disease: Value and limitations of a potential marker of neoplasia.
Dobrescu R; Picu C; Caragheorgheopol A; Manda D; Ioachim D; Goldstein A; Badiu C
Cancer Biomark; 2020; 29(3):337-346. PubMed ID: 32716342
[TBL] [Abstract][Full Text] [Related]
7. Downregulation of miR-381 is associated with poor prognosis in papillary thyroid carcinoma.
Huang T; Yi D; Xu L; Bu E; Zhu C; Sang J; Zhang Y
Int J Clin Exp Pathol; 2017; 10(12):11610-11616. PubMed ID: 31966518
[TBL] [Abstract][Full Text] [Related]
8. Clinical value of matrix metalloproteinase-2 and -9 in ultrasound-guided radiofrequency ablation treatment for papillary thyroid carcinoma.
Pan Q; Yuan T; Ding Q
J Int Med Res; 2020 Aug; 48(8):300060520917581. PubMed ID: 32772889
[TBL] [Abstract][Full Text] [Related]
9. Predictive Value of Serum Thyroglobulin for Structural Recurrence Following Lobectomy for Papillary Thyroid Carcinoma.
Xu S; Huang H; Zhang X; Huang Y; Guan B; Qian J; Wang X; Liu S; Xu Z; Liu J
Thyroid; 2021 Sep; 31(9):1391-1399. PubMed ID: 34340593
[No Abstract] [Full Text] [Related]
10. Dynamic monitoring of circulating microRNAs as a predictive biomarker for the diagnosis and recurrence of papillary thyroid carcinoma.
Zhang Y; Xu D; Pan J; Yang Z; Chen M; Han J; Zhang S; Sun L; Qiao H
Oncol Lett; 2017 Jun; 13(6):4252-4266. PubMed ID: 28599426
[TBL] [Abstract][Full Text] [Related]
11. The role of matrix metalloproteinase-9 as a prognostic biomarker in papillary thyroid cancer.
Zarkesh M; Zadeh-Vakili A; Akbarzadeh M; Fanaei SA; Hedayati M; Azizi F
BMC Cancer; 2018 Dec; 18(1):1199. PubMed ID: 30509240
[TBL] [Abstract][Full Text] [Related]
12. Combination of serum microRNAs and ultrasound profile as predictive biomarkers of diagnosis and prognosis for papillary thyroid microcarcinoma.
Zhang Y; Pan J; Xu D; Yang Z; Sun J; Sun L; Wu Y; Qiao H
Oncol Rep; 2018 Dec; 40(6):3611-3624. PubMed ID: 30542708
[TBL] [Abstract][Full Text] [Related]
13. Serum-plasma matched metabolomics for comprehensive characterization of benign thyroid nodule and papillary thyroid carcinoma.
Huang FQ; Li J; Jiang L; Wang FX; Alolga RN; Wang MJ; Min WJ; Ma G; Zhao YJ; Wang SL; Yu Y; Chen X; Zhu D; Zhu J; Wang G; Xia T; Sang JF; Lai MD; Li P; Zhu W; Qi LW
Int J Cancer; 2019 Feb; 144(4):868-876. PubMed ID: 30318614
[TBL] [Abstract][Full Text] [Related]
14. Diagnostic significance of elevated expression of HBME-1 in papillary thyroid carcinoma.
Chen YJ; Zhao RM; Zhao Q; Li BY; Ma QY; Li X; Chen X
Tumour Biol; 2016 Jul; 37(7):8715-20. PubMed ID: 26738867
[TBL] [Abstract][Full Text] [Related]
15. Papillary thyroid cancer, although strongly associated with lymphocytic infiltration on histology, is only weakly predicted by serum thyroid auto-antibodies in patients with nodular thyroid diseases.
Fiore E; Rago T; Scutari M; Ugolini C; Proietti A; Di Coscio G; Provenzale MA; Berti P; Grasso L; Mariotti S; Pinchera A; Vitti P
J Endocrinol Invest; 2009 Apr; 32(4):344-51. PubMed ID: 19636204
[TBL] [Abstract][Full Text] [Related]
16. Serum miR-22 may be a biomarker for papillary thyroid cancer.
Wang D; Guo C; Kong T; Mi G; Li J; Sun Y
Oncol Lett; 2019 Mar; 17(3):3355-3361. PubMed ID: 30867770
[TBL] [Abstract][Full Text] [Related]
17. Overexpression of serum lncRNA-ABHD11-AS1 as poor prognosis of patients with papillary thyroid carcinoma.
Hou S; Zhuang YY; Lin QY; Chen Z; Zhao HG; Zhang L; Lin CH
Exp Mol Pathol; 2021 Aug; 121():104658. PubMed ID: 34102210
[TBL] [Abstract][Full Text] [Related]
18. Immunohistochemical levels of matrix metalloproteinase-2 and CD44 variant 6 protein in the diagnosis and lateral cervical lymph node metastasis of papillary thyroid carcinoma.
Wu G; Zhou Y; Li T; Guo J; Zhou Z
J Int Med Res; 2013 Jun; 41(3):816-24. PubMed ID: 23685894
[TBL] [Abstract][Full Text] [Related]
19. Immunohistochemical levels of cyclo-oxygenase-2, matrix metalloproteinase-9 and vascular endothelial growth factor in papillary thyroid carcinoma and their clinicopathological correlations.
Meng XY; Zhang Q; Li Q; Lin S; Li J
J Int Med Res; 2014 Jun; 42(3):619-27. PubMed ID: 24670538
[TBL] [Abstract][Full Text] [Related]
20. Expression of matrix metalloproteinase-2 and its tissue inhibitor-2 in fetal and neoplastic thyroid tissue and their significance as diagnostic and prognostic markers in papillary carcinoma.
Marečko I; Cvejić D; Tatić S; Dragutinović V; Paunović I; Savin S
Cancer Biomark; 2011-2012; 11(1):49-58. PubMed ID: 22820140
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
